In the Claims:

Claims 1-99 (Canceled).

100. (New) A method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.

101. (New) The method of claim 100, wherein said compound is selected from the group consisting of:

(a) a molecule capable of binding said AMP and/or AMP-like molecule;

(b) an enzyme capable of cleaving said AMP and/or AMP-like molecule;

(c) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule;

(d) a DNAzyme capable of cleaving an mRNA or DNA encoding said AMP and/or AMP-like molecule;

(e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule;

(f) a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule;

(g) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule;

(h) a molecule capable of inhibiting activation or ligand binding of said AMP and/or AMP-like molecule; and

(i) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.

102. (New) The method of claim 101, wherein said molecule capable of binding said AMP and/or AMP-like molecule is an antibody or an antibody fragment.

103. (New) The method of claim 100, wherein said AMP and/or AMP-like molecule is a beta-defensin.

104. (New) The method of claim 100, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.

105. (New) The method of claim 100, wherein the disease is selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, and an endothelial disease.

106. (New) An article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease being associated with a biological process in a cell and/or tissue, the biological process being selected from the group consisting of growth, differentiation, inflammation, metastasis and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule.

107. (New) The article of manufacture of claim 106, wherein said compound is selected from the group consisting of:

(a) a molecule capable of binding said AMP and/or AMP-like molecule;

(b) an enzyme capable of cleaving said AMP and/or AMP-like molecule;

(c) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule;

(d) a DNAzyme capable of cleaving an mRNA or DNA encoding said AMP and/or AMP-like molecule;

(e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule;

(f) a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule;

(g) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule; and

(h) a molecule capable of inhibiting activation or ligand binding of said AMP and/or AMP-like molecule; and

(i) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.

108. (New) The article of manufacture of claim 107, wherein said molecule capable of binding said AMP is an antibody or an antibody fragment.

109. (New) The article of manufacture of claim 106, wherein said AMP and/or AMP-like molecule is a beta-defensin.

110. (New) The article of manufacture of claim 106, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.

111. (New) The article of manufacture of claim 106, wherein said disease is selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, an endothelial disease and a human disease.

112. (New) The article of manufacture of claim 106, wherein said disease is psoriasis or skin carcinoma.

113. (New) A method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.

114. (New) The method of claim 113, wherein said providing to the subject said AMP and/or AMP-like molecule is effected by administering said AMP and/or AMP-like molecule to the subject and/or by expressing said AMP and/or AMP-like molecule in the subject.

115. (New) The method of claim 113, wherein said AMP and/or AMP-like molecule is a beta-defensin.

116. (New) The method of claim 113, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1, beta-defensin-2 and LL-37.

117. (New) The method of claim 113, wherein the disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.

118. (New) An article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease being associated with a biological process in a cell and/or tissue, said biological process being selected from the group consisting of growth, differentiation, inflammation and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an antimicrobial peptide (AMP) and/or AMP-like molecule.

119. (New) The article of manufacture of claim 118, wherein said AMP and/or AMP-like molecule is a beta-defensin.

120. (New) The article of manufacture of claim 118, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.

121. (New) The article of manufacture of claim 118, wherein said disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.